In the SURPASS-2 study, the three doses of tirzepatide (5, 10, and 15 mg once weekly) were tested with the GLP-1RA semaglutide (1 mg once weekly) as a comparator in patients not optimally controlled on monotherapy with metformin (71)
Besides improving glucose control, reducing body weight, and lowering arterial blood pressure (surrogate endpoints), the breakthroughs were the demonstration of a significant reduction in cardiovascular and renal events in patients with type 2 diabetes at high risk
12-week response check
Key Takeaways GLP-1 therapy can lead to average weight loss of 518% according to clinical trials
Our program specifically addresses the components of metabolic syndrome that accelerate aging: Insulin Resistance : Tirzepatide dramatically improves insulin sensitivity, helping your cells use glucose more efficiently Visceral Fat : Targeted reduction of dangerous abdominal fat that contributes to inflammation Lipid Profiles : Improved cholesterol ratios and triglyceride levels Blood Pressure : Natural reduction through weight loss and improved vascular function The Longevity Benefits You Can Expect Cellular Health and Anti-Aging Early research indicates that tirzepatide, through its effects on GIP and GLP-1 receptors, may offer neuroprotective benefits, potentially lowering the risk of neurodegenerative diseases like Alzheimers
If these technologies mature to the point where a 39-amino acid peptide can be reliably delivered orally with clinically meaningful bioavailability, an actual oral tirzepatide pill becomes possible